TLR7 agonist 1

TLR7 agonist 1 is a selective and oral TLR7 agonist (IC50: 90 nM).

TLR7 8 agonist 1 dihydrochloride (TLR7 8 agonist-5d) 是 toll 样受体TLR7 TLR8的双重激动剂。

TLR7 agonist14（compound 17b）作为一种TLR7激动剂，具有高效性，其EC50值为59 nM。在低纳摩尔级别浓度下，TLR7 agonist14能有效激活小鼠巨噬细胞以及hPBMC。

TLR7 agonist15（compound 16b）作为一种高效的TLR7激动剂，其EC50值为59 nM。在低纳摩尔浓度下，该化合物能够有效诱导小鼠巨噬细胞和hPBMC的激活。

TLR7 agonist16 (compound 16d)为一种高效的TLR7激动剂，具有EC50值为59 nM。在低纳摩尔水平上，它可以有效激活小鼠巨噬细胞和hPBMC。

TLR7 agonist 17 (compound 20) functions as a highly effective TLR7 agonist, exhibiting EC 50 values of 12 nM for hTLR7 and 17 nM for mTLR7. Additionally, this compound has demonstrated anticancer activity [1].

TLR7 agonist19 (Compound 14) 是一种具有优良药代动力学特性并具有协同抗肿瘤活性的Toll样受体7 (TLR7) 激动剂。

TLR7 agonist 10 is a Nucleoside Derivative - Xylo-nucleoside, N-Methylated alkylated nucleoside; 8-Modified purine nucleoside.

TLR7 agonist 13 是一种有用的有机化合物，可用于生命科学领域的相关研究。其产品编号为 TNU1350，CAS号为 2389988-70-7。

TLR7 agonist12 (example 20) 是一种针对惰性淋巴系统恶性肿瘤具有广泛抗肿瘤活性的TLR7激动剂及嘌呤核苷类似物。其抗癌机制主要通过抑制DNA合成和诱导细胞凋亡(apoptosis)来实现。

D18 is an immune modulator that acts as a dual agonist for TLR7 8 (with EC50 values of 24 nM for hTLR7 and 10 nM for hTLR8, respectively). It enhances the expression of PD-L1 through epigenetic regulation, thereby increasing the sensitivity of tumors to PD-1 PD-L1 blockade. Additionally, D18 functions as a cytotoxin for ADC synthesis, specifically for the ADC HE-S2 [1].

TLR7 agonist 2 (TLR7-IN-1) 是选择性 Toll 样受体 7 激动剂，LEC 值为 0.4 μM。

1V209 (TLR7 agonist T7) 是一种 Toll 样受体 7 (TLR7) 激动剂，可与各种多糖缀合，以改善其水溶性，增强功效并保持低毒性，具有抗肿瘤作用。

AXC-715 trihydrochloride (T785 trihydrochloride) 是一种 TLR7 TLR8 双激动剂， 可用于合成抗体佐剂免疫偶联物。偶联物多为程序性死亡配体 1 (PD-L1) 连接到一个或多个佐剂的抗体结构上。

GSK2245035 is a highly selective intranasal TLR7 agonist with preferential Type-1 interferon (IFN)-stimulating properties (pEC50s: 9.3 and 6.5 for IFNα and TFNα). It effectively suppresses allergen-induced Th2 cytokine production in human peripheral blood

3M-011, a potent dual toll-like receptor TLR7 8 agonist and cytokine inducer, serves as a powerful adjuvant to radiotherapy, eliciting significant local and systemic immune responses. Additionally, it effectively inhibits H3N2 influenza viral replication in the nasal cavity and exhibits strong antitumor activity[1][2][3].

Gardiquimod 可抑制巨噬细胞和活化的外周血单个核细胞的HIV-1感染。 它是一种咪唑喹啉类似物，是一种 TLR7 8 激动剂。

Gardiquimod (hydrochloride) 是一种咪唑啉类的TLR7 8激动剂。它能够抑制巨噬细胞和激活外周血单个核细胞 (PBMCs) 的HIV-1感染。当浓度低于10 μM时，Gardiquimod (hydrochloride) 可以特异性地激活TLR7。

TLR7 agonist 29 (Compound 1) 是一种TLR7激动剂，人TLR7的EC50为5.2 nM（小鼠TLR7的EC50为48.2 nM）。它可以激活骨髓来源的巨噬细胞 (BMDM)，刺激肿瘤微环境中的髓系细胞，并促进PD-L1、CD86和IFN-α的表达。TLR7 agonist 29 还可用作合成ADC的有效载荷。

TLR7 agonist 30 (compound 2) 是一种用于 ADC 的药物-接头结合物 (drug-linker conjugate for ADC)。它由 TLR7 激动剂 (compound 1) 与一个可裂解的连接子构成，展示出显著的抗肿瘤活性。

Imiquimod hydrochloride (R 837 hydrochloride) 是一种选择性的 toll 样受体 7 (TLR7) 激动剂和免疫反应调节剂，具有抗病毒和抗肿瘤活性。Imiquimod hydrochloride 可用于研究天疱疮叶状疱疮、皮肤癌和银屑病。

AXC-715 hydrochloride is a TLR7/TLR8 dual agonist, can be used for synthesis of antibody-adjuvant immunoconjugates, comprising an antibody construct that binds programmed death-ligand 1 (PD-L1) linked to one or more adjuvants.

Gardiquimod diTFA，咪唑啉类似物TLR7 8激动剂，可特异性抑制巨噬细胞和活化外周血单个核细胞(PBMCs)的HIV-1感染。在浓度低于10 μM时，该化合物特异性激活TLR7。

TLR7 8 agonist 4 (compound 41) 是具有抗癌活性的，TLR7 8 的有效激动剂。